Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report

gene rearrangements occur in 1% to 2% of NSCLC. Acquired “on-target” mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired ROS1 G2101A resistance mutation after first-line cri...

Descripción completa

Detalles Bibliográficos
Autores principales: Begum, Parvin, Cui, Wanyuan, Popat, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372631/
https://www.ncbi.nlm.nih.gov/pubmed/35966191
http://dx.doi.org/10.1016/j.jtocrr.2022.100376
_version_ 1784767429502566400
author Begum, Parvin
Cui, Wanyuan
Popat, Sanjay
author_facet Begum, Parvin
Cui, Wanyuan
Popat, Sanjay
author_sort Begum, Parvin
collection PubMed
description gene rearrangements occur in 1% to 2% of NSCLC. Acquired “on-target” mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired ROS1 G2101A resistance mutation after first-line crizotinib, who responded to lorlatinib. The response was dramatic but short in duration.
format Online
Article
Text
id pubmed-9372631
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93726312022-08-13 Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report Begum, Parvin Cui, Wanyuan Popat, Sanjay JTO Clin Res Rep Case Report gene rearrangements occur in 1% to 2% of NSCLC. Acquired “on-target” mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired ROS1 G2101A resistance mutation after first-line crizotinib, who responded to lorlatinib. The response was dramatic but short in duration. Elsevier 2022-07-05 /pmc/articles/PMC9372631/ /pubmed/35966191 http://dx.doi.org/10.1016/j.jtocrr.2022.100376 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Begum, Parvin
Cui, Wanyuan
Popat, Sanjay
Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
title Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
title_full Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
title_fullStr Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
title_full_unstemmed Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
title_short Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
title_sort crizotinib-resistant ros1 g2101a mutation associated with sensitivity to lorlatinib in ros1-rearranged nsclc: case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372631/
https://www.ncbi.nlm.nih.gov/pubmed/35966191
http://dx.doi.org/10.1016/j.jtocrr.2022.100376
work_keys_str_mv AT begumparvin crizotinibresistantros1g2101amutationassociatedwithsensitivitytolorlatinibinros1rearrangednsclccasereport
AT cuiwanyuan crizotinibresistantros1g2101amutationassociatedwithsensitivitytolorlatinibinros1rearrangednsclccasereport
AT popatsanjay crizotinibresistantros1g2101amutationassociatedwithsensitivitytolorlatinibinros1rearrangednsclccasereport

Ejemplares similares